Free Trial

Alice Nettleton Analyst Performance

Analyst at UBS Group

Alice Nettleton is a stock analyst at UBS Group in the healthcare sector, covering 13 publicly traded companies. Over the past year, Alice Nettleton has issued 13 stock ratings, including buy and hold recommendations. While full access to Alice Nettleton's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Alice Nettleton's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
61.54% 8 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy61.5%8 ratings
Hold38.5%5 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Alice Nettleton at UBS Group, the majority (61.5%) have been Buy recommendations, followed by 38.5% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.3% of companies on NASDAQ
12 companies
NYSE
7.7% of companies on NYSE
1 company

Alice Nettleton, an analyst at UBS Group, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
13 companies
100.0%

Alice Nettleton of UBS Group specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
10 companies
76.9%
PHARMACEUTICALS
3 companies
23.1%

Alice Nettleton's Ratings History at UBS Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
10/12/2026Initiated Coverage$12.55$18.00Buy
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
10/11/2026Initiated Coverage$23.33$26.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
10/11/2026Initiated Coverage$85.69$120.00Buy
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
10/11/2026Reiterated Rating$10.30$19.00Buy
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
10/11/2026Initiated Coverage$6.34$8.00Neutral
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
10/11/2026Initiated Coverage$23.37$29.00Neutral
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10/11/2026Initiated Coverage$5.97$17.00Buy
Evommune, Inc. stock logo
EVMN
Evommune
10/11/2026Initiated Coverage$6.24$8.00Neutral
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
10/11/2026Initiated Coverage$7.54$14.00Buy